GlassScriptPhysician profile
Jose R Prieto
NPI 1093748428
$2,105.73
in general payments reported to CMS, 2019-2025
20 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $93.37 · 2021: $129 · 2022: $682 · 2023: $489 · 2024: $20.19 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $332.53 | 2019-2025 | Dovato, Cabenuva |
| Melinta Therapeutics, LLC | $278.26 | 2019-2023 | Orbactiv, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $268.52 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Gilead Sciences, INC. | $254.43 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $171.69 | 2019-2021 | |
| Abbvie INC. | $149.64 | 2022-2023 | |
| Atricure, INC. | $125.06 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Janssen Biotech, INC. | $90.34 | 2019-2023 | Symtuza |
| Insmed, INC. | $84.75 | 2021-2022 | |
| Allergan, INC. | $64.34 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $47.78 | 2022-2023 | Nuzyra |
| Octapharma USA, INC. | $45.61 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $43.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.08 | 2019-2022 | |
| Shionogi INC | $24.47 | 2023 | Fetroja |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $22.98 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $21.70 | 2025 | Shingrix |
| Astellas Pharma US INC | $20.19 | 2024 | Veozah |
| Novo Nordisk INC | $16.96 | 2022 | |
| Smith+Nephew, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.